SUPN stock forecast, quote, news & analysis
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company... Show more
Why Supernus Pharmaceuticals (SUPN) Stock Is Down -30% in the Last 30 Days
Key Takeaways
- SUPN declined roughly 30% over the past 30 days, from about $42.38 to around $29.80, with the sharpest move tied to the completion of its merger with Indivior.
- The all-stock transaction left legacy Supernus shareholders holding about 43.5% of the combined company, while Indivior holders received a pre-close dividend funded in part by new debt.
- Record Q3 2026 results — revenue of $226.8 million (up 18.1% year over year) and adjusted EPS of $0.88 — did not offset the post-merger repricing.
- Over the trailing three months, the stock has fallen about 35% from the mid-$40s as a steady downtrend accelerated in early November.
- Core growth brands Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI continue to expand, and management is targeting $125 million in annual cost synergies.
- For additional detail on valuation and expectations, explore SUPN's Price Targets, Earnings, and Forecast pages.
- Traders can also review the Trending AI Robots section for current AI-driven strategies.
Supernus Pharmaceuticals (SUPN) Company Overview and Market Position
Supernus Pharmaceuticals is a Rockville, Maryland-based biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its marketed portfolio includes Qelbree for attention-deficit hyperactivity disorder (ADHD), GOCOVRI for dyskinesia in Parkinson's disease, Oxtellar XR and Trokendi XR for epilepsy, APOKYN and XADAGO for Parkinson's disease, MYOBLOC for cervical dystonia and chronic sialorrhea, ONAPGO for motor fluctuations in advanced Parkinson's disease, and ZURZUVAE for postpartum depression through a collaboration with Biogen. Investors follow the stock for its expanding CNS franchise, prescription growth in key brands, and a pipeline of earlier-stage neuroscience candidates.
Supernus Pharmaceuticals (SUPN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SUPN fell from roughly $42.38 to about $29.80, a decline of approximately 29.7%. The move was not gradual: shares traded mostly in the low $40s through late October before dropping sharply in the first sessions of November as the merger closed.
The trailing three-month picture is similar in direction but larger in magnitude. Beginning August near the mid-$40s, the stock drifted lower through September and October and then accelerated downward into early November, leaving it down roughly 35% over the period. The 52-week range of $37.54 to $59.68 underscores how far the stock has retraced from earlier highs.
What Drove SUPN Stock Price in the Last 30 Days
The dominant catalyst was the completion of Supernus's all-stock merger with Indivior, announced as closed on November 2, 2026. The combined company, renamed Supernus, Inc., began trading under the SUPN ticker on November 3, with legacy Supernus shareholders owning approximately 43.5% of the enlarged entity.
The deal's capital structure weighed heavily on sentiment. Indivior shareholders received a pre-close cash dividend reported at roughly $1 billion, funded in part by about $650 million in new debt placed on the combined company — while Supernus shareholders did not receive that dividend. The resulting dilution and added leverage triggered a sharp repricing of the stock, which outweighed otherwise strong operating results.
Fundamental news was positive during the same window. On October 29, Supernus reported record third-quarter revenue of $226.8 million, up 18.1% year over year, with adjusted EPS of $0.88 versus roughly $0.49 consensus, and raised full-year 2026 revenue guidance to a range of $875 million to $900 million. The company also announced that the FDA granted ONAPGO seven years of orphan drug exclusivity. Separately, Supernus was replaced by Huron Consulting Group in the S&P SmallCap 600 index effective in early November, a change that can generate index-driven selling pressure.
What Drove SUPN Stock Performance Over the Last Quarter
Beyond the merger, the quarter reflected a longer-standing disconnect between improving fundamentals and a declining share price. Throughout August and September, the stock trended lower even as Qelbree prescriptions grew 18% year over year, ZURZUVAE collaboration revenue advanced, and ONAPGO recovered from earlier supply constraints. Investors also weighed the intangible asset impairment charges the company affirmed for full-year 2026, along with the uncertain economics of the pending Indivior combination.
The broader narrative over the quarter was one of a growing, profitable CNS franchise that nonetheless faced a structurally dilutive and debt-funded merger, culminating in the sharp early-November re-rating. Management's $125 million annual synergy target and the expanded combined portfolio represent the primary integration goals investors are now watching.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's AI-driven trading bots. Tickeron hosts hundreds of automated bots that monitor thousands of tickers, but only the top-performing and most relevant strategies are highlighted in this section. Each bot varies by strategy, timeframe, and performance metrics, allowing traders to compare approaches that range from short-term signals to longer-horizon models. The section is designed to help users identify AI-generated trading ideas that are currently active in the market. Traders interested in systematic, data-driven signals can explore the page to review available bots and their recent performance.
SUPN Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investors are likely to focus on the integration of Supernus and Indivior, including the realization of the $125 million cost-synergy target and the combined entity's capital structure following the added debt. Clarity on the enlarged company's full-year 2027 guidance, expected in early 2027, is a key milestone. Continued prescription momentum in Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI, along with pipeline progress on candidates such as SPN-820 and SPN-817, will also shape sentiment. Analyst consensus remains a Buy with an average price target of $60.50, though investors should weigh that against the post-merger share count, leverage, and execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SUPN in upward trend: price may jump up because it broke its lower Bollinger Band on October 27, 2026
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where SUPN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SUPN's RSI Oscillator exited the oversold zone, 22 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on SUPN as a result. In 75 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 223 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SUPN turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 29 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for SUPN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.477) is normal, around the industry mean (6.379). P/E Ratio (-13.625) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.202). SUPN's Dividend Yield (1.243) is considerably higher than the industry average of (0.062). P/S Ratio (2.863) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SUPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer for the treatment of central nervous system
Industry PharmaceuticalsGeneric